Update on Rotarix: an oral human rotavirus vaccine
- PMID: 19943758
- DOI: 10.1586/erv.09.136
Update on Rotarix: an oral human rotavirus vaccine
Abstract
Worldwide, rotaviruses are the single most important agents of severe gastroenteritis in infants and young children. Globally, it is estimated that every year rotavirus gastroenteritis causes more than 125 million episodes of diarrhea and nearly 527,000 deaths, mainly in developing countries. The development of new effective and safe rotavirus vaccines was recognized as the most effective intervention strategy that could yield a significant impact on the burden of rotavirus disease. Rotarix is an oral live-attenuated human rotavirus vaccine containing a single G1P[8] strain. The first oral dose may be administered as early as 6 weeks of age, with a minimum interval of 4 weeks prior to second dose; the vaccination course should be completed by the age of 24 weeks according to the manufacturer. In the USA, the upper age limit for the second dose has recently been recommended at 32 weeks of age by the Advisory Committee on Immunization Practices. The development program for Rotarix including Phase I, II and III multicenter studies involving over 100,000 infants has been established in Latin America, Europe, Asia and Africa. The vaccine proved to be well tolerated, immunogenic, efficacious, safe and not associated with intussusception. It provided 85-96% protection against severe rotavirus gastroenteritis caused by G1 and non-G1 serotypes in Latin American and European clinical trials; and of public health importance, Rotarix reduced hospitalizations of all-cause gastroenteritis by 40 and 75%, respectively. Efficacy against G2P[4] strains ranged from 41% in Latin America to 81% in Europe. In the former, Rotarix afforded sustained high protection (80.5%; 95% CI: 71.3-87.1) against severe rotavirus gastroenteritis during the first 2 years of life in a region with a changing pattern of wild-type rotavirus circulation. In a recently completed vaccine trial in South Africa and Malawi, Rotarix showed an overall efficacy of 61.2% (95% CI: 44.0-73.2) by 1 year of age. Although these rates are lower than those from developed and middle-income countries, they look promising given the lack of other effective interventions. With the expanding introduction of rotavirus vaccines into national immunization programs, postmarketing surveillance should be conducted to measure the impact of rotavirus vaccination, as well as continued monitoring of circulating rotavirus strains.
Similar articles
-
Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa.J Infect Dis. 2010 Sep 1;202 Suppl:S80-6. doi: 10.1086/653547. J Infect Dis. 2010. PMID: 20684722
-
Rotarix (RIX4414): an oral human rotavirus vaccine.Expert Rev Vaccines. 2007 Feb;6(1):11-9. doi: 10.1586/14760584.6.1.11. Expert Rev Vaccines. 2007. PMID: 17280473 Review.
-
Live attenuated human rotavirus vaccine, Rotarix.Semin Pediatr Infect Dis. 2006 Oct;17(4):188-94. doi: 10.1053/j.spid.2006.08.006. Semin Pediatr Infect Dis. 2006. PMID: 17055369 Review.
-
Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.Vaccine. 2009 Oct 9;27(43):5936-41. doi: 10.1016/j.vaccine.2009.07.098. Epub 2009 Aug 11. Vaccine. 2009. PMID: 19679216 Clinical Trial.
-
RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.Expert Rev Vaccines. 2008 Dec;7(10):1475-80. doi: 10.1586/14760584.7.10.1475. Expert Rev Vaccines. 2008. PMID: 19053204 Review.
Cited by
-
The protective role of prebiotics and probiotics on diarrhea and gut damage in the rotavirus-infected piglets.J Anim Sci Biotechnol. 2024 May 3;15(1):61. doi: 10.1186/s40104-024-01018-3. J Anim Sci Biotechnol. 2024. PMID: 38698473 Free PMC article. Review.
-
Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice.Viruses. 2024 Jan 31;16(2):211. doi: 10.3390/v16020211. Viruses. 2024. PMID: 38399987 Free PMC article.
-
Oral Vaccines: A Better Future of Immunization.Vaccines (Basel). 2023 Jul 12;11(7):1232. doi: 10.3390/vaccines11071232. Vaccines (Basel). 2023. PMID: 37515047 Free PMC article. Review.
-
Bivalent rotavirus VP4∗ stimulates protective antibodies against common genotypes of human rotaviruses.iScience. 2022 Sep 8;25(10):105099. doi: 10.1016/j.isci.2022.105099. eCollection 2022 Oct 21. iScience. 2022. PMID: 36185383 Free PMC article.
-
Immunity to enteric viruses.Immunity. 2022 May 10;55(5):800-818. doi: 10.1016/j.immuni.2022.04.007. Immunity. 2022. PMID: 35545029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical